New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
07:31 EDTANAC, SGMO, XLRN, MDCO, INSY, GERN, EGRX, DSCO, ARGS, THLDPiper Jaffray to hold a symposium
Catalyst Symposium to be held in Boston on July 8.
News For ANAC;ARGS;DSCO;EGRX;GERN;INSY;MDCO;XLRN;SGMO;THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 29, 2014
05:59 EDTINSYInsys Therapeutics initiated with an Overweight at Piper Jaffray
Subscribe for More Information
October 28, 2014
11:32 EDTMDCOThe Medicines Co. reports Phase III FINISH-3 trial data publication
The Medicines Company announced the presentation of the results of the pivotal Phase III clinical trial of the investigational hemostatic agent RAPLIXA, formerly known as Fibrocaps, at the 100th Clinical Congress of the American College of Surgeons in San Francisco, CA. As previously reported, the Phase III trial, FINISH-3, which studied a total of 719 patients, met all primary and secondary hemostasis efficacy endpoints in four distinct surgical indications of spinal surgery, hepatic resection, vascular surgery and soft tissue dissection. RAPLIXA, currently under regulatory review with the FDA and the European Medicines Agency, is a dry powder topical formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery. The results were published simultaneously in the Journal of the American College of Surgeons, the company said.
10:40 EDTMDCOHigh option volume stocks
Subscribe for More Information
08:10 EDTMDCOAlnylam, The Medicines Co. file application to initiate Phase 1 ALN-PCSsc study
Subscribe for More Information
07:21 EDTINSYCBI to hold a conference
Subscribe for More Information
04:58 EDTMDCOThe Medicines Co. wins favorable judgement in Angiomax patent litigation
The Medicines Company (MDCO) announced the U.S. District Court for the Northern District of Illinois in The Medicines Company v. Mylan, Inc. entered judgment in favor of The Medicines Company on all issues concerning U.S. Patent No. 7,582,727. Following a June 2014 trial, Judge Amy St. Eve found all of the asserted claims are infringed by Mylanís (MYL) Abbreviated New Drug Application, or ANDA. The same claims were also found to be valid and enforceable. Mylanís ANDA seeks FDA approval to commercially manufacture, use or sell a generic version of The Medicines Companyís Angiomax drug product before the expiration of the í727 patent. The ruling prevents Mylan from obtaining FDA approval of its generic bivalirudin and launching its ANDA product until the earlier of a successful appeal or expiration of the í727 patent in 2028. To appeal successfully, Mylan must overturn the Courtís rulings on each of the asserted claims.
October 27, 2014
18:34 EDTMDCOMedicines Co. wins patent suit against Mylan, Bloomberg reports
The Medicines Co. (MDCO) has won a patent suit against Mylan (MYL), Bloomberg reports. A U.S. district court found that Mylan infringed the Medicines Co. patent for its blood-clot-inhibiting drug Angiomax. Shares of Medicines Co. are up 11.5% to $24.76 following the report. Reference Link
October 24, 2014
10:08 EDTXLRNAcceleron to host educational seminar
Subscribe for More Information
07:26 EDTXLRNAcceleron data positive, says JMP Securities
JMP Securities believes that data presented on Acceleron's sotatercept shows compelling evidence of clinical benefit to dialysis patients. The firm thinks the data supports the drug's efficacy in preventing vascular calcification. It reiterates a $52 price target and Outperform rating on the shares.
October 23, 2014
10:54 EDTXLRNAcceleron, Celgene to present sotatercept prelinical interim clinical data
Acceleron Pharma (XLRN) reported that its collaboration partner, Celgene (CELG), and investigators on the sotatercept program will present sotatercept preclinical and interim clinical data at the American Society of Nephrology Kidney Week 2014. The meeting will be held in Philadelphia on November 11-16. Preliminary data, including safety and effects on hemoglobin, bone density and vascular calcification from the ongoing phase 2a clinical trial of sotatercept will be presented on Thursday, November 13. Additionally, data from preclinical studies will be presented on Friday and Saturday, November 13 and 14.
10:01 EDTMDCOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 3D Systems (DDD) downgraded to Hold from Buy at Brean Capital... Angie's List (ANGI) downgraded to Hold from Buy at Needham... Avalon Rare Metals (AVL) downgraded to Neutral from Buy at Citigroup... Axiall (AXLL) downgraded at Cowen... BB&T (BBT) downgraded to Neutral from Buy at Goldman... Boeing (BA) downgraded at Credit Suisse... Boulder Brands (BDBD) downgraded to Hold from Buy at Canaccord... Citrix (CTXS) downgraded to Hold from Buy at Drexel Hamilton... ClickSoftware (CKSW) downgraded to Hold from Buy at Lake Street... DTS, Inc. (DTSI) downgraded to Underweight from Neutral at JPMorgan... GulfMark Offshore (GLF) downgraded to Market Perform from Outperform at Cowen... Home Loan Servicing (HLSS) downgraded to Neutral from Buy at Compass Point... ICON plc (ICLR) downgraded to Equal Weight from Overweight at First Analysis... IPC The Hospitalist Co. (IPCM) downgraded to Market Perform at Wells Fargo... Melco Crown (MPEL) downgraded to Neutral from Buy at Nomura... Mercer (MERC) downgraded at Credit Suisse... ONEOK Partners (OKS) downgraded to Neutral from Buy at BofA/Merrill... Owens Corning (OC) downgraded to Neutral from Overweight at JPMorgan... Regency Energy Partners (RGP) downgraded to Neutral from Buy at BofA/Merrill... The Medicines Co. (MDCO) downgraded to Neutral from Buy at BofA/Merrill... Tupperware Brands (TUP) downgraded to Neutral from Overweight at JPMorgan... Union Bankshares (UBSH) downgraded at RW Baird... VOC Energy Trust (VOC) downgraded at RBC Capital... Yelp (YELP) downgraded to Hold from Buy at Stifel.
06:46 EDTMDCOThe Medicines Co. downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
October 22, 2014
16:12 EDTSGMOSangamo backs FY14 revenue view $45M-$50M, consensus $47.57M
Subscribe for More Information
16:06 EDTSGMOSangamo reports Q3 EPS (11c), consensus (14c)
Subscribe for More Information
10:02 EDTARGSArgos Therapeutics breaks ground on new 100K square foot facility
Subscribe for More Information
09:45 EDTMDCOThe Medicines Co. says 'as open as can possibly be' to potential takeover
Subscribe for More Information
09:21 EDTMDCOThe Medicines Co. lowers 2014 revenue outlook to $720M-$735M
Subscribe for More Information
07:11 EDTMDCOMedicines Co. says Angiomax, Angiox revenue up 5% in first nine months
Subscribe for More Information
07:06 EDTMDCOThe Medicines Co. reports Q3 EPS (26c) , consensus (12c)
Subscribe for More Information
October 20, 2014
09:48 EDTMDCOBrdiger Management reports 5.1% passive stake in The Medicines Co.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use